Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (580)	1/10/2002 10:20:21 AM
From: tuck	Read Replies (1) \| Respond to of 1005

BLUE HP deploys a little cash by buying 500 shares more DDDP for $7.93, the current ask. Otherwise trying to be patient, and would be happy to get suggestions.

To: tuck who wrote (580)	1/11/2002 4:03:36 PM
From: tuck	Read Replies (1) \| Respond to of 1005

Nigel, I should qualify my post regarding chemistry companies available for munching. EBIO is purely a reagent company and thus a much different animal than DPII. It might get munched by another trickle company, but you won't see it getting munched for its drug discovery capabilities, of which it has none. Thus a deal like DCGN/MCLS would involve DPII, not EBIO. I think PCOP is still a munch candidate of similar flavor to DPII, though that and EBIO are a bit OT here, given that they aren't BLUE H stocks. Have to find out if the shareholders approved the Eos munch by PCOP; everyone seems to hate that deal. I'd like to see PCOP spin out Accelrys -- giving BLUE HP more grist for its mill -- and then get munched. Or something like that. I suspect that's what most folks would like to see. Edit: vote on Eos munch is on 1/18. I don't like the deal, either, and PCOP might rebound on a "no" vote. Cheers, Tuck